Table II.

Outcomes for Post-CY following RIC for patients with Hematologic Malignancies (N=49)

	% Cumulative Incidence	95% C.I.
Acute GVHD Grade II–IV at Day 100	53%	(40–70)
Acute GVHD Grade III–IV at day 100	22%	(13–38)
Chronic GVHD at 1 year	18%	(9–33)
Day 100 TRM	14%	(7–28)
1-year TRM	31%	(20–47)
CMV reactivation (patients at risk)	54%	(40–72)
Progression at 2 years
Overall	26%	(17–42)
AML in CR1 or CR2	18%	(5–64)
AML > CR2	31%	(18–53)
PFS at 2 years
Overall	26%	(15–39)
AML in CR1 or CR2	36%	(11–63)
AML > CR2	24%	(11–40)
OS at 2 years
Overall	33%	(20–46)
AML in CR1 or CR2	36%	(11–63)
AML > CR2	31%	(16–48)